Meropenem Sun

Meropenem, the active ingredient in Meropenem Sun, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It is employed to treat severe bacterial infections, including complicated intra‑abdominal infections, complicated urinary tract infections, hospital‑acquired pneumonia, septicemia, and meningitis, primarily in hospitalized adult patients.

GNH USA supplies Meropenem Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across global markets.

Meropenem Sun is a broad‑spectrum carbapenem used for serious bacterial infections affecting various organ systems.

- Complicated intra‑abdominal infections: provides bacterial eradication in the peritoneal cavity. - Complicated urinary tract infections: eliminates resistant uropathogens causing pyelonephritis. - Hospital‑acquired pneumonia: treats Gram‑negative and Gram‑positive pathogens in ventilated patients. - Septicemia: rapidly clears bloodstream infections. - Meningitis: penetrates the cerebrospinal fluid to treat central nervous system infections.

Adverse reactions may occur with any intravenous antibiotic and should be monitored during therapy.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Infusion site reactions: redness, pain, or phlebitis at the injection site. - Rash: mild skin erythema. - Elevated liver enzymes: transient increase in hepatic transaminases. - Headache: occasional mild headache.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Clostridioides difficile colitis: risk of severe intestinal infection. - Neutropenia: marked reduction in white blood cells. - Renal toxicity: worsening kidney function in susceptible individuals. - Severe hypersensitivity: including Stevens‑Johnson syndrome.

Careful assessment and monitoring are required before and during treatment with Meropenem Sun.

- Renal function: adjust dosing in patients with impaired renal clearance. - Allergy: avoid in individuals with known hypersensitivity to carbapenems or β‑lactams. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Valproic acid co‑administration: monitor for reduced plasma levels of valproate. - Superinfection: watch for overgrowth of non‑susceptible organisms, such as fungi or C. difficile. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem Sun may interact with other medicines; some combinations require avoidance while others need close monitoring.

Major Interactions (Avoid): - Valproic acid: co‑administration can markedly reduce valproate concentrations. - Renally toxic drugs (e.g., amphotericin B): increased risk of kidney injury. - CNS‑active agents (e.g., quinolones, antiepileptics): heightened seizure risk.

Moderate Interactions (Monitor Closely): - Loop diuretics: monitor renal function and electrolytes. - Aminoglycosides: assess for additive nephrotoxicity. - Other antibiotics: potential antagonism when combined with bacteriostatic agents.